Ampio Pharmaceuticals announces allowance of composition and methods patent for Ampion

Tuesday August 8, 2017 0 comments Tags: Englewood, Ampio Pharmaceuticals, Michael Macaluso, Ampion

 

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced the allowance of an important composition and methods patent in the U.S. complimenting a series of patents on Ampion™ (127 issued and 80 pending).Ampio_logoUSE

The patent is entitled: "COMPOSITIONS FOR THE MOBILIZATION, HOMING, EXPANSION, AND DIFFERENTIATION OF STEM CELLS AND METHODS OF USING THE SAME."  

The patent includes 34 allowed claims.

Autologous or allogenic stem cells are used in clinical practice, including for osteoarthritis of the knee. Ampio said Ampion has demonstrated in-vitro effects on mesenchymal stem cells on recruitment and differentiation.

This process occurs naturally in the body, however, to augment the number of stem cells that would survive after injection in the body and their differentiation into tissue specific cells (chondrocytes making collagen/cartilage in the case of osteoarthritis), incubating them with Ampion prior to injection is the subject of this patent.

"This patent expands the potential indications of Ampion to conditions where stem cells are administered to patients, mimicking natural in-vivo processes in which a patient's stem cells are recruited to the site of inflammation,” said Michael Macaluso, Ampio’s CEO.

“Also, because stem cell therapy is becoming a valid therapeutic option, Ampion could be used in conjunction with stem cells to maximize and synergize the desired safe and beneficial effect in osteoarthritis including pain relief."

Ampio said the existing Ampion portfolio has patent coverage in all major jurisdictions throughout the world (U.S., EuropeAustraliaBrazilCanadaChina, Eurasia, Hong KongIndiaIndonesiaIsraelJapan, Korea, MexicoMalaysiaNew ZealandPhilippinesSingaporeSouth Africa) for pharmaceutical compositions and methods of treating a range of conditions.

The portfolio includes 127 issued patents and 80 pending applications throughout seven primary patent families having expiration dates that extend to 2035.